1. Introduction {#sec1}
===============

Cardiac allograft vasculopathy (CAV) is a major cause of graft loss and death after heart transplantation (HTx). Identification of surrogate makers for late cardiac allograft survival has been of major interest to improve long-term outcomes of HTx \[[@B1]\]. After HTx, alloantigens (including molecules from donor endothelium) are presented by antigen-presenting cells to the recipient\'s T-cells, often generating a differentiated inflammatory response. That response includes T-cells, B-cells, and a coordinated pattern of cytokine release. Cells of innate immunity (monocyte-derived macrophages) are also involved \[[@B1]\]. Non-antigen-specific perioperative events including microvascular insults may play pivotal roles related to subsequent development of CAV, probably related to ischemia reperfusion injury, advanced donor age, hyperlipidemia, depletion of arteriolar tissue plasminogen activator factor and systemic inflammation \[[@B1]--[@B8]\]. The inflammatory response culminates in migration of mononuclear cells through the coronary vascular endothelium and phenotypic switching of medial smooth muscle cells mediated by generation of growth-promoting cytokines. Those processes contribute to chronic damage of the coronary arteries of the transplanted heart. The result is the development of a diffuse, obliterative form of vasculopathy characterized by production of a "neointima" rich in vascular smooth muscle cells and extracellular matrix \[[@B9], [@B10]\]. After the first year post-transplantation, 30% to 50% of patients have some evidence of CAV and after 5 years CAV is one of the leading causes of death with \<50% 1-year survival rate in those with extended disease \[[@B11], [@B12]\].

Limited interventions have been shown to prevent, delay, or reverse CAV. While no definite well-validated surrogate marker for late cardiac allograft outcome is available, early detection of CAV represents the *key* strategy as an effective surrogate \[[@B1]\]. Early identification of CAV became possible with the introduction of intravascular ultrasound (IVUS) \[[@B13]\], but the technique is invasive, it is usually not initiated until at least one year post-transplantation, is expensive, and requires the use of nephrotoxic contrast agents. Noninvasive tests, including stress perfusion, dobutamine echocardiography, ultrafast tomography, and MRI have not proven to be sufficiently sensitive or specific to detect early stages of the disease \[[@B14], [@B15]\]. Therefore, there are clear needs to explore and develop new options for the early evaluation of patients at risk of CAV.

Recently, gene expression profiles of peripheral blood mononuclear cells (PBMC) were used to identify patients with \[[@B16], [@B17]\] or without moderate and severe acute cellular cardiac allograft rejection \[[@B18]\] and patients at risk of antibody-mediated rejection \[[@B19]\].

Since the peripheral recirculation of recipient leukocytes after allo-endothelial-cell contact in the allograft may carry information about immune activation conducive to chronic rejection development, we hypothesized that gene expression profiles of PBMC obtained early after HTx carry molecular signatures that correlate with the future development of CAV.

2. Materials and Methods {#sec2}
========================

2.1. Patients, Samples, and Microarrays {#sec2.1}
---------------------------------------

We analyzed a limited set of 41,000 gene expression profiles (whole-genome Microarray, Agilent Technologies, Wilmington, DE) obtained from patients included in a large multicenter study (Cardiac Allograft Rejection Gene Expression Observational \[CARGO\] study) that used microarrays to identify PBMC gene signatures of acute cellular cardiac allograft rejection \[[@B18]\]. Columbia University Medical Center (CUMC) contributed 121 patients. Out of the Columbia University cohort, independent whole genome PBMC samples from 10 patients were available. The study protocol was approved by the Institutional Review Board (IRB) of CUMC. PBMC were isolated from eight mL of venous blood using density gradient centrifugation (CPT, Becton-Dickinson, Franklin Lakes, NJ). Samples were frozen in lysis buffer (RLT, Qiagen, Valencia, CA) within 2 h of phlebotomy. Total RNA was isolated from each sample (RNeasy, Qiagen, Valencia, CA). Whole genome gene expression profiling was performed on two-color Whole Human Genome 60-mer Oligo Microarrays (Agilent Technologies, Santa Clara, CA), which contain 41,000+ unique transcripts. After the hybridization, data were extracted and Lowess normalized expression files were generously provided by the CARGO study sponsor (XDx Inc., Brisbane, CA). Filtering was done against background and only those probes with more than 1.5-fold change were retained. Probes mapping to the same gene transcript were not averaged.

2.2. Cardiac Allograft Vasculopathy {#sec2.2}
-----------------------------------

Patients were eligible for the study if they were evaluated with angiography during their post-transplant course. CAV was defined as any evidence of disease in the angiography as evaluated by one of three expert interventional cardiologists who specialized in heart transplantation care at the Center for Interventional Vascular Therapy at Columbia University. Angiograms were classified as normal (no evidence of vasculopathy), mild (any grade of angiographic luminal stenosis less than 50%), moderate (any angiographic luminal stenosis greater than 50% in a main vessel or two secondary branches), and severe (more than 50% in the left main or two main vessels). Patients with moderate or severe CAV were considered "advanced".

2.3. Statistical Analysis {#sec2.3}
-------------------------

Quantitative and qualitative clinical variables were compared by the Mann Whitney *U*-test, Chi-Square test, or Fischer-exact when appropriate using SPSS 11.5.1 (SPSS Inc., 2002). A *P*-value \<.05 was regarded as significant. Gene expression of samples obtained from patients with advanced CAV was compared against those with normal or mild disease using independent, unpaired *t*-test, and Benjamini-Hochberg correction for multiple comparisons to estimate a false discovery rate (FDR) as implemented in significance analysis of microarrays (SAM) \[[@B20]\] after 1.5-fold change filtering. Genes were retained for further analyses if FDR \< 5%. Molecular function and biological processes associated with individual significant genes were determined using PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification System (<http://www.pantherdb.org>), a unique resource that classifies genes by their functions, using published scientific experimental evidence and evolutionary relationships to predict function even in the absence of direct experimental evidence. Quantitative, real-time PCR cycle thresholds (CT) for each group were compared with the Mann Whitney *U*-test. *P*-value \<.05 was considered significant.

2.4. Hierarchical Clustering {#sec2.4}
----------------------------

Gene expression data were correlated and visualized in clustered heat maps \[[@B23]\] using the Genesis web interface (([http://carmaweb.genome.tugraz.at/](http://carmaweb.genome.tugraz.at/genesis/index2.html) [genesis/index2.html](http://carmaweb.genome.tugraz.at/genesis/index2.html)), Institute for Genomics and Bioinformatics, Graz University of Technology, Graz, Austria). Top 100 genes and microarray samples as well as differentially enriched GO categories and genes were clustered on the basis of co-occurrence of the differentially expressed genes using the Pearson metric and average linkage.

2.5. Gene Ontology Analysis {#sec2.5}
---------------------------

We used High-Throughput GoMiner (HTGM) \[[@B21]\] (<http://discover.nci.nih.gov/>) to analyze the list of interesting genes in the context of gene ontology (GO) categories \[[@B22]\]. HTGM analyzes data from all microarrays in a study, provides diagnostics for data interpretation and visualization tools in terms of specialized clustered "heat maps" (also called clustered image maps, CIMs) \[[@B23]\]. Normally, the input to HTGM consists of a total-genes file (representing the entire Microarray or a randomly generated whole genome seed) and a changed-genes file (representing the genes with altered expression) relevant to the study purpose. The output generated by HTGM includes a summary of the results, a matrix whose rows are categories and whose columns are names of changed gene for hierarchical clustering of experiments and categories, and a statistical summary for each category including one-sided Fisher exact *P*-value and an FDR. Hierarchical clustering of enriched categories and changed genes allows determining which categories achieved statistical significance by virtue of containing essentially the same set of changed genes.

3. Results {#sec3}
==========

3.1. Patient Demographics {#sec3.1}
-------------------------

The baseline characteristics of the study population, including mean age, gender, race, diagnosis, mean cold ischemia time, induction strategy, antirejection prophylaxis, median follow-up time at the time that the microarrays were obtained, median follow-up time till the diagnosis of CAV, simvastatin use, and median number of rejection episodes (i.e., 1R/1B, 2R, and 2R/3A) requiring augmented immunosuppression are depicted in Tables [1](#tab1){ref-type="table"}(a) and [1](#tab1){ref-type="table"}(b) for the overall population and by study subgroups and sample method. All baseline clinical characteristics were comparable across groups in both microarray and PCR studies. Although the difference in timing of blood sample post-HTx between advanced CAV and normal/mild CAV groups in the microarray study population approached the defined level of significance (*P* = .06) but this difference was not significant in the PCR study population.

3.2. Microarray Analysis {#sec3.2}
------------------------

Out of 10 patients who were studied with microarrays, 3 (30%) had advanced CAV while 7 (70%) had angiograms consistent with either absence of disease (*n* = 3, 30%) or mild disease (*n* = 4, 40%). Comparison of study samples for each study group is summarized in [Table 1(a)](#tab1){ref-type="table"}. One sample that had 2R (moderate) cellular cardiac allograft rejection was retained given the limited small Microarray dataset.

3.3. RT-PCR Analysis {#sec3.3}
--------------------

There were 64 Quantitative, 253 transcript, Real-Time PCR samples available from our Center, obtained from 43 patients during the CARGO study \[[@B18]\]. Nine samples from 9 patients associated with ISHLT grade 3A/2R rejection and 1 sample without rejection grading information were excluded. Out of the remaining samples, 3 samples had no angiographic information, 1 sample had aneurismatic disease diagnosed at year 1 without further information in subsequent years, and 18 samples from 13 patients were repeated. For repeated samples, we choose the one closest to the median time from the transplant surgery to the date that all samples were obtained. Therefore, we retained 33 samples obtained from 33 patients for this analysis. Twenty-eight PCR samples (85%) belonged to patients from the normal (*n* = 20) or mild disease (*n* = 8) group, and 5 samples (15%) belonged to patients with advanced CAV.

3.4. Gene Expression Profiles {#sec3.4}
-----------------------------

Between-group comparisons identified 316 transcripts from 291 unique genes differentially expressed with FDR ≤ 5%: 182 transcripts (170 genes) were up-regulated and 134 transcripts (123 genes) were down-regulated. Top up- and down-regulated genes and their functions are depicted in ([Table 2](#tab2){ref-type="table"}) and a clustered heat map of top 100 up- and down-regulated genes is shown in ([Figure 1](#fig1){ref-type="fig"}). A complete list of genes with their respective fold changes and false discovery rates is provided as supplementary material available online at doi:10.1155/2010/719696.

3.5. Gene Ontology Analysis {#sec3.5}
---------------------------

HTGM detected 18 changed GO categories (FDR \< 5%) enriched with differentially expressed genes ([Table 3](#tab3){ref-type="table"}). Processes related to enriched GO categories included among others: macrophage activation, response to wounding, response to virus, response to biotic stimulus, interleukin-6 biosynthetic process, I-kappaB kinase NF-kappaB cascade, innate immune response, inflammatory response, regulation of interleukin-6 biosynthetic process, defense response, positive regulation of interleukin-6 biosynthetic process, activation of NF-kappaB-inducing kinase, and interleukin-6 production. Evaluation of the clustered image map indicates potential cross-talk among GO categories enriched by advanced CAV genes. Instances of cross-talk are of particular importance because they tie together categories that, based on prior knowledge, might be thought of as unrelated. A clustered heat map of differentially expressed genes and enriched gene ontology categories and cross-talk is shown in ([Figure 2](#fig2){ref-type="fig"}).

3.6. RT-PCR Validation {#sec3.6}
----------------------

We compared the list of 291 candidate genes that we identified by SAM based on 5% FDR for this exploratory study with the 252 candidate gene list of the available RT-PCR generated in the Discovery Phase of the CARGO study \[[@B18]\]. We found 8 transcripts (7 different genes) overlapping. The validation rate based on Mann Whitney *U*-test comparison between absence of, or mild CAV (*n* = 28) and advanced CAV (*n* = 5) was 75% (2 not validated out of 8). Validated genes included FPRL1 (*P* = .005), S100A9 (*P* = .005), CXCL10 transcript 1 (*P* = .009), and CXCL10 transcript 2 (*P* = .019), PRO1073 (*P* = .045), MMP9 (*P* = .045). Nonvalidated genes included ENO1 (0.083) and FAS (*P* = .104). SAM-based differentially expressed genes and the corresponding RT-PCR gene *P*-values showed good concordance ([Table 4](#tab4){ref-type="table"}).

4. Discussion {#sec4}
=============

A gene signature is the group of genes in a type of cell whose combined expression pattern is a unique characteristic of a disease under investigation. These disease specific gene signatures can be used to select patients at a specific state of a disease with an accuracy that facilitates the diagnosis of the disease and selection of patients for different treatment options.

In this pilot study, patients with advanced CAV show peripheral blood gene expression profiles that differ already in the early period after transplantation from those of patients who will not develop advanced CAV. The findings are consistent with previous suggestions that donor- and recipient-related factors in the perioperative period may play major roles in the immune response and development of a sustained chronic response to immune injury, leading to proliferation of the endovascular matrix, with consequent obstruction of the blood flow and impairment of allograft function \[[@B2], [@B4], [@B9], [@B10]\].

In previous studies, gene expression profiles of PBMC have been shown to correlate with presence or absence of *concurrent* acute cellular rejection \[[@B16]--[@B18], [@B34]\], antibody mediated rejection \[[@B19]\], and in response to mechanical circulatory support device implantation \[[@B35], [@B36]\]. Based on these gene expression profiles, the genomic classifier developed to rule out acute cellular cardiac allograft rejection has also been shown to correlate with different organ function related parameters of rejection \[[@B32], [@B33]\], and longitudinal changes in clinical profiles \[[@B37], [@B38]\]. In current study, we hypothesized that gene signatures early after HTx correlate with *future* development of CAV. To the best of our knowledge, this is the first report of using a high throughput genomic screening approach to identify patients at risk of developing advanced CAV on the basis of leukocyte samples obtained during the early period after transplantation. This observation has potentially important implications.

Recently CAV has been reported as one of the major causes of new-onset graft dysfunction and associated outcomes \[[@B39]\]. Early detection of CAV was proposed as the *key* strategy, to identify surrogate markers for late cardiac allograft outcomes \[[@B1]\]. Currently, the most accurate diagnostic test to define the phenotype of CAV is intravascular ultrasound \[[@B9]\]. Evaluation of the neointimal proliferation rate between months 3 and 12 has been shown to predict survival and major adverse cardiac events at long-term follow-up \[[@B11]\] but intravascular ultrasound is invasive, expensive and complication prone. Therefore, early profiling of an immune response that differentiates a "high CAV-risk phenotype" from a "low CAV-risk phenotype" may become valuable to early identify these patients, model timely therapeutic interventions and monitor response.

This concept in HTx is not new. Earlier observations in animal models of rejection suggested that "unstable tolerance induction" is associated with the persistent immune activation that mediates destruction of graft parenchymal cells, and that the evaluation of biological processes involved might be useful in identifying different types of rejection and the likelihood of progression to chronic forms \[[@B25]\].

In our study, we found differentially expressed genes that significantly enriched GO categories including the innate immunity, macrophage activation, interleukin-6, activation of the NF-KappaB cascade and response to virus. The finding that the innate immune response plays an important role is interesting because it has been already described in the literature. Differentially expressed genes, among others in this category, included Toll-like receptors 1, 4 and 6, and Interleukin-23 alpha. Several authors proposed an important role of innate immunity in the pathogenesis of CAV \[[@B10], [@B26]--[@B28]\]. For example, it has been shown that in patients with allograft endothelial dysfunction (an early clinical indicator of transplant vasculopathy), mRNA transcript level and surface expression of TLR-4 on circulating monocyte is significantly higher than controls \[[@B27]\]. According to our results the categories related to these mechanisms were enriched by the down-regulated genes. The interaction between the up- and down-regulated genes collectively determines the functioning of different biological processes as assessed by high through-put microarray analysis. Our observations show some interesting expression patterns of these mechanisms during the *early* period post-HTx which needs further understanding. Therapy with Simvastatin that inhibits allograft inflammatory activity and attenuates endothelial coronary dysfunction shows reduced trans-cardiac IL-6 and TNF-alpha gradients \[[@B26]\] and polymorphisms within the promoter region of the IL-6 gene has been proposed as risk markers for CAV \[[@B29]\]. In addition, the transcription factor NFKB becomes up-regulated in response to CD40/ CD40 ligand mediating apoptosis of endothelial cells. Inhibition of this pathway has been shown to be protective against the development of CAV \[[@B30]\]. The GO analysis shows that the STAT1 gene involved in the NFKB pathway is also part of the response to virus showing a "cross-talk" between both categories and suggesting that mechanisms of immune damage related to viruses (i.e., CMV) \[[@B9], [@B10]\] may be related to the NFKB pathway.

The findings presented in this paper should encourage the development of strategies to advance evaluation and management of heart transplant recipients in a preventative, preemptive and personalized way, but the conclusion from this pilot study should be interpreted within the important limitations imposed by the small sample size, the use of angiography which is an imperfect standard for detection of CAV, and the known variable reproducibility of gene expression studies \[[@B31]\]. Corroboration of genes was based on retrospective PCR data. Only a small number of genes were available that were present in the Microarray-based candidate gene list.

*In conclusion,* our data show that peripheral blood leukocyte genes, specifically innate immune response genes, are differentially expressed during the early time after HTx in patients who develop advanced CAV. Larger prospectively designed studies are needed to corroborate our findings.
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###### 

Supplementary Appendix 1: This supplementary material includes the complete list of differentially expressed genes including the probe ID, Gene Symbol and Gene Name along with the information on degree of fold change, q-value, and direction of regulation in advanced CAV as compared to the normal or mild disease.

Supplementary Appendix 2: This supplementary material includes the complete list of the GO categories enriched by the significantly differentially expressed genes, including category names with the number of total and changes genes in individual category. It also includes the one-sided Fisher exact p-value and the false discovery rate as calculated by the HTGM algorithm.

###### 

Click here for additional data file.

###### 

Click here for additional data file.
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![Clustered heat map of top 100 up- and down-regulated genes in patients with advanced transplant coronary artery disease and controls. Gene symbol and gene name are provided when available. Platform unique identifier is provided otherwise.](JTRAN2010-719696.001){#fig1}

![Clustered heat map of enriched GO categories by differentially expressed genes. Instances of cross-talk are shown that links GO categories enriched by similar genes. The green areas show GO categories enriched by the down-regulated genes while small red areas in the corners show GO categories enriched by up-regulated genes.](JTRAN2010-719696.002){#fig2}

###### 

Baseline clinical characteristics. Baseline Clinical Characteristics Comparing Microarray and PCR Study Populations.

###### 

\(a\)

                                Microarray study (*N* = 10)   PCR study (*N* = 33)                                              
  ----------------------------- ----------------------------- ---------------------- ------ ----------------- ----------------- ------
  Time after HTx (days)         232  (81--298)                42  (41--96)           .067   81  (7--171)      55  (41--167)     .643
  Follow-up time (years)        5.3  (4.8--5.8)               5.6  (5.4--5.7)        .138   5.5  (4.6--6.2)   5.7  (5.1--5.8)   .315
  Male gender recipient         6  (85.7%)                    3  (100%)              1      21  (75.0%)       4  (80%)          1
  Male gender donor             6  (85.7%)                    2  (66.7%)             1      20  (71.4%)       3  (60%)          .627
  Caucasian recipient           5  (71.4%)                    3  (100%)              .585   21  (63.6%)       5  (100%)         .903
  Caucasian donor               7  (100%)                     1  (33%)               .67    17  (60.7%)       2  (40%)          .685
  Recipient age                 55.6 ± 8.2                    48.5 ± 13.5            .383   52.6 ± 105        61.4 ± 8          .173
  Donor age                     31.7 ± 11.7                   44.1 ± 7.9             .183   32.8 ± 13.0       41.5 ± 13.7       .226
  ICM recipient                 5  (71.4%)                    1  (33.3%)             .11    14  (50%)         4  (80%)          .267
  LVAD                          3  (42.9%)                    2  (66.7%)             1      7  (21.2%)        2  (40%)          .597
  Recipient CMV (+)             2  (28.6%)                    0  (0.00%)             .53    11  (33.3%)       2  (40%)          .347
  Donor CMV (+)                 3  (42.9%)                    2  (40.0%)             .7     14  (50%)         4  (80%)          .445
  Ischemic time (Min)           188.7 ± 65.1                  138 ± 36.6             .229   183.9 ± 49.2      156 ± 7           .208
  Daclizumab induction          7  (100%)                     3  (100%)              ---    24  (85.7%)       4  (80%)          
  Prednisone                    7  (100%)                     3  (100%)              ---    28  (100%)        5  (100%)         ---
  Prednisone dose               8.71 ± 7.8                    13.3 ± 2.9             .296   16.3 ± 10.2       13.0 ± 4.5        .359
  Maintenance Regimen                                                                1                                          .295
   Cyclosporine                 6  (85.7%)                    3  (100%)                     24  (85.7%)       4  (80%)          
   Tacrolimus                   1  (14.3%)                    0  (0.0%)                     3  (10.7%)        0  (0%)           
   Sirolimus                    0  (0.0%)                     0  (0.0%)                     1  (3.6%)         1  (20%)          
  Cyclosporine levels (ng/ml)   437.0 ± 489                   225.3 ± 26             .655   312.5 ± 226       229.25 ± 22       .212
  Tacrolimus levels (ng/ml)     8.5 ± 0.2                     ---                    ---    11.7 ± 2.5        ---               ---
  Sirolimus levels (ng/ml)      ---                           ---                    ---    6                 5.6               ---
  Mycophenolate                 6  (85.7%)                    3  (100%)              1      24  (85.7%)       5  (100%)         1
  Azathioprine                  0  (0.0%)                     0  (0.0%)              ---    0  (0.0%)         0  (0.0%)         ---
  Simvastatin                   1  (14%)                      1  (33%)               1.00   2  (7%)           0  (0%)           1.00
  Cellular rejection (ISHLT)                                                         .161                                       .78
   0R                           4  (57.1%)                    2  (66.7%)                    24  (85.7%)       4  (80%)          
   1R                           3  (42.9%)                    0  (0.0%)                     4  (14.3%)        1  (20%)          
   2R                           0  (0.0%)                     1  (33.3%)                    0  (0%)           0  (0%)             
  New episodes of rejection                                                                                                     
   1R/1B                        0  (0--1)                     0  (0--0)              .513   0  (0--4)         0  (0--3)         .688
   2R                           1  (0--1)                     1  (0--1)              .789   0  (0--2)         0  (0--1)         .375
   2R/3A                        0  (0--1)                     0  (0--0)              .513   0  (0--2)         0  (0--3)         .898

HTx: heart transplant; LVAD: left ventricular assist device; RT-PCR: real-time polymerase chain reaction.

###### 

\(b\)

                                Normal or mild    Advanced CAV      Microarray versus PCR (*N* = 43)                                                                            
  ----------------------------- ----------------- ----------------- ---------------------------------- ----------------- ----------------- ------ -------------- -------------- ------
  Time after HTx (days)         232  (81--298)    81  (7--171)      .002                               42  (41--96)      55  (41--167)     .571   154.5 ± 99.5   76.4 ± 47.5    .037
  Follow-up time (years)        5.3  (4.8--5.8)   5.5  (4.6--6.2)   .433                               5.6  (5.4--5.7)   5.7  (5.1--5.8)   .451   5.3 ± 0.3      5.4 ± 0.4      .583
  Male gender recipient         6  (85.7%)        21  (75%)         1                                  3  (100%)         4  (80%)          1      9  (90%)       25  (75.8%)    .659
  Male gender donor             6  (85.7%)        20  (21.4%)       .648                               2  (66.7%)        3  (60%)          1      8  (80%)       23  (69.7%)    .698
  Caucasian recipient           5  (71.4%)        21  (75%)         .781                               3  (100%)         5  (100%)                8  (80%)       26  (78.8%)    .823
  Caucasian donor               7  (100%)         17  (60.7)        .26                                1  (33.3%)        2  (40%)          .641   8  (80%)       19  (57.6%)    .433
  Recipient age                 55.6 ± 8.2        52.6 ± 10.5       .43                                48.6 ± 13.5       61.4 ± 8.0        .393   53.5 ± 9.8     53.9 ± 10.5    .916
  Donor age                     31.7 ± 11.6       32.8 ± 13.0       .888                               44.1 ± 7.9        41.55 ± 13.6      1      35.4 ± 11.8    34.1 ± 13.3    .559
  ICM recipient                 5  (71.4%)        14  (50%)         .941                               1  (33.3%)        4  (80%)          .293   6  (60%)       18  (54.5%)    .668
  LVAD                          3  (42.9%)        7  (25%)          .31                                2  (66.7%)        2  (40%)          1      5  (50%)       9  (27.3%)     .252
  Recipient CMV (+)             2  (28.6%)        11  (39.3%)       .523                               0  (0.0%)         2  (40%)          .449   2  (20%)       13  (39.4%)    .291
  Donor CMV (+)                 3  (42.9%)        14  (50%)         .822                               2  (66.7%)        4  (80%)          1      5  (50%)       18  (54.5%)    .904
  Ischemic times (Min)          188.75 ± 65.13    183.9 ± 49.2      .706                               138.0 ± 36.6      156.0 ± 7         .786   167 ± 57.5     178.7 ± 45.6   .495
  Daclizumab induction          7  (100%)         24  (85.7%)       .562                               3  (100%)         4  (80%)                 10  (100%)     28  (84.8%)    .32
  Prednisone                    7  (100%)         28  (100%)        ---                                3  (100%)         5  (100%)                10  (100%)     33  (100%)     
  Prednisone dose               8.7 ± 7.8         16.3 ± 10.2       .015                               13.3 ± 2.9        13.0 ± 4.5        .845   10.1 ± 6.8     15.79 ± 9.5    .041
  Maintenance regimen                                               .85                                                                    .4                                   .727
   Cyclosporine                 6  (85.7%)        24  (85.7%)                                          3  (100%)         4  (80%)                 9  (90%)       28  (84.8%)    
   Tacrolimus                   1  (14.3%)        3  (10.7%)                                           0  (0.0%)         0  (0.0%)                1  (10%)       3  (9.1%)      
   Sirolimus                    0  (0.0%)         0  (0.0%)                                            0  (0.0%)         1  (20%)                 0  (0.0%)      2  (6.1%)      
  Cyclosporine levels (ng/ml)   437.0 ± 489.4     312.5 ± 226       .686                               225.3 ± 26.6      229.25 ± 22.6     1      357.6 ± 386    300.6 ± 211    .47
  Tacrolimus levels (ng/ml)     8.5 ± 0.2         11.7 ± 2.5        .083                               ---               ---                      8.5 ± 0.2      11.7 ± 2.5     .083
  Sirolimus levels (ng/ml)      ---               6                                                    ---               5.6                      ---            11.7 ± 2.5     ---
  Mycophenolate                 6  (85.7%)        24  (85.7%)       1                                  3  (100%)         5  (100%)                9  (90%)       28  (84.8%)    1
  Azathioprine                  0  (0.0%)         0  (0.0%)         ---                                0  (0.0%)         0  (0.0%)         ---    0  (0.0%)      0  (0.0%)      ---
  Simvastatin                   1  (14%)          2  (7%)           .499                               1  (33%)          0  (0%)           .375   2  (20%)       2  (6%)        .226
  Cellular rejection (ISHLT)                                        .123                                                                   .315                                 .127
   0R                           4  (57.1%)        24  (85.7%)                                          2  (66.7%)        4  (80%)                 6  (60%)       28  (84.8%)    
   1R                           3  (42.9%)        4  (14.3%)                                           0  (0.0%)         1  (20%)                 3  (30%)       5  (15.1%)     
   2R                           0  (0.0%)         0  (0.0%)                                            1  (33.3%)        0  (0.0%)                1  (10%)       0  (0.0%)        
  New Episodes of Rejection                                                                                                                                                     
   1R/1B                        0  (0--1)         0  (0--4)         .3                                 0  (0--0)         0  (0--3)         .439   0  (0--1)      0  (0--4)      .17
   2R                           1  (0--1)         0  (0--2)         .59                                1  (0--1)         0  (0--1)         .217   1  (0--1)      0  (0--2)      .32
   2R/3A                        0  (0--1)         0  (0--2)         .4                                 0  (0--0)         0  (0--3)         .439   0  (0--1)      0  (0--3)      .235

HTx: heart transplant; LVAD: left ventricular assist device; RT-PCR: real time polymerase chain reaction.

###### 

Highest differentially expressed genes from whole genome Microarray analysis.

  GS         Gene name                                                             Gene molecular function/Gene biological process                                                                  FDR   FC    Up/Down
  ---------- --------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ----- ----- ---------
  ANKRD22    Ankyrin repeat domain 22                                              Data not found                                                                                                   0     4.5   Up
  BATF2      Basic leucine zipper transcription factor, ATF-like 2                 DNA binding and transcription factor activity                                                                    0     2.6   Up
  CD38       CD38 molecule                                                         Hydrolase activity in hydrolyzing N-glycosyl compounds and lyase activity                                        0     2.1   Up
  DCLRE1B    DNA cross-link repair 1B (PSO2 homolog, S. cerevisiae)                Nucleobase, nucleoside, nucleotide, and nucleic acid metabolic process                                           0     1.9   Up
  EGR1       Early growth response 1                                               RNA binding, DNA binding, and transcription factor activity                                                      0     4.9   Up
  EPSTI1     Epithelial stromal interaction 1 (breast)                             Data not found                                                                                                   0     3.2   Up
  FAM26F     Family with sequence similarity 26, member F                          Data not found                                                                                                   0     2.6   Up
  FCGR1B     Fc fragment of IgG, high affinity Ib, receptor (CD64)                 Receptor activity                                                                                                0     2.8   Up
  FLJ11783   Data not found                                                        Data not found                                                                                                   0     0.4   Down
  GNB4       Guanine nucleotide binding protein (G protein), beta polypeptide 4    GTPase activity and protein binding                                                                              0     2.3   Up
  IFI44      Interferon-induced protein 44                                         Data not found                                                                                                   0     3.1   Up
  IFI44L     Interferon-induced protein 44-like                                    Data not found                                                                                                   0     4.8   Up
  IFI6       In multiple clusters                                                  Immune system process                                                                                            0     2.9   Up
  IFIT1      Interferon-induced protein with tetratricopeptide repeats 1           Response to interferon-gamma and response to stimulus                                                            0     7.1   Up
  IFIT2      Interferon-induced protein with tetratricopeptide repeats 2           Response to interferon-gamma and response to stimulus                                                            0     4.8   Up
  IFIT3      Interferon-induced protein with tetratricopeptide repeats 3           Response to interferon-gamma and response to stimulus                                                            0     7.4   Up
  IFITM2     Interferon-induced transmembrane protein 2 (1-8D)                     Immune system process                                                                                            0     2.9   Up
  IFITM3     Interferon-induced transmembrane protein 3 (1-8U)                     Immune system process                                                                                            0     2.6   Up
  IFITM4P    Leukocyte Ig-like receptor, subfamily A (with TM domain), member 2    Data not found                                                                                                   2     2.0   Up
  ISG15      Leukocyte Ig-like receptor, subfamily A (with TM domain), member 5    Ligase activity, apoptosis, and protein metabolic process                                                        2     4.4   Up
  LY6E       Lymphocyte antigen 6 complex, locus E                                 Data not found                                                                                                   0     2.8   Up
  MMP8       Matrix metallopeptidase 8 (neutrophil collagenase)                    Peptidase activity and protein metabolic process                                                                 0     5.2   Up
  MX1        Influenza virus resistance 1, IFN-inducible protein p78 (mouse)       GTPase activity, protein binding, intracellular protein transport, and endocytosis                               0     3.0   Up
  OAS2       2′--5′-oligoadenylate synthetase 2, 69/71 kDa                         Nucleotidyltransferase activity, nucleic acid binding, response to interferon-gamma, and response to stimulus    0     3.2   Up
  PLAC8      Placenta-specific 8                                                   Data not found                                                                                                   0     3.0   Up
  PLSCR1     Phospholipid scramblase 1                                             Immune system process, lipid transport, lipid metabolic process, and blood coagulation                           0     2.4   Up
  RSAD2      Radical S-adenosyl methionine domain containing 2                     Data not found                                                                                                   0     5.6   Up
  SCARB2     Scavenger receptor class B, member 2                                  Macrophage activation, lipid transport, apoptosis, signal transduction, cell adhesion, lipid metabolic process   0     2.3   Up
  SIGLEC1    Sialic acid binding Ig-like lectin 1, sialoadhesin                    B cell mediated immunity, signal transduction, cell-cell adhesion, and response to stimulus                      0     7.8   Up
  CXCL10     Chemokine (C-X-C motif) ligand 10                                     Macrophage activation, cell-cell signaling, cell motion, signal transduction, and cellular defense response      1     3.4   Up
  EIF2AK2    Eukaryotic translation initiation factor 2-alpha kinase 2             Immune system process, cell cycle, protein metabolic process, and response to stress                             1     2.1   Up
  LAP3       Leucine aminopeptidase 3                                              Protein metabolic process                                                                                        1     3.0   Up
  LCP1       Lymphocyte cytosolic protein 1 (L-plastin)                            Structural constituent of cytoskeleton, cytoskeletal protein binding, and cellular component morphogenesis       1     1.9   Up
  SECTM1     Secreted and transmembrane 1                                          Data not found                                                                                                   1     1.9   Up
  SERPING1   Serpin peptidase inhibitor, clade G, member 1, (Angioedema)           Protein binding, peptidase inhibitor activity, and protein metabolic process                                     1     3.0   Up
  STXBP2     Syntaxin binding protein 2                                            Neurotransmitter secretion, intracellular protein transport, exocytosis, and synaptic transmission               1     2.1   Up
  SULT1A1    Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1   Transferase activity, sulfur metabolic process, and lipid metabolic process                                      1     2.1   Up
  TBRG1      Transforming growth factor beta regulator 1                           Receptor binding                                                                                                 1     0.4   Down
  BLOC1S1    Biogenesis of lysosome-related organelles complex-1, subunit 1        DNA binding and transcription factor activity                                                                    2     1.9   Up
  BST2       Bone marrow stromal cell antigen 2                                    Data not found                                                                                                   2     2.0   Up
  CCDC84     Coiled-coil domain containing 84                                      Data not found                                                                                                   2     0.4   Down
  CDC14A     CDC14 cell division cycle 14 homolog A (S. cerevisiae)                Mitosis, phosphate metabolic process, and protein metabolic process                                              2     0.5   Down
  FLJ32679   In multiple clusters                                                  Data not found                                                                                                   2     0.5   Down
  FLJ38379   Hypothetical protein FLJ38379                                         Data not found                                                                                                   2     0.4   Down
  HERC5      Hect domain and RLD 5                                                 Protein metabolic process, ectoderm development, mesoderm development, and skeletal system development           2     3.6   Up

GS: Gene Symbol; FDR: false discovery rate; FC: fold change; Up/Down: regulation in advanced versus normal or mild CAV.

###### 

Gene ontology categories enriched by genes expressed differentially between patients with and without advanced CAV.

  Regulation in Adv-CAV   Number of genes   GO category type     Exemplary GO categories
  ----------------------- ----------------- -------------------- -----------------------------------------------------------------------
  Up-/Down-regulated      291               Biological process   GO:0006955 immune response
                                                                 GO:0002376 immune system process
                                                                 GO:0051707 response to other organism
                                                                 GO:0009607 response to biotic stimulus
                                                                 GO:0006954 inflammatory response
                                                                 GO:0050896 response to stimulus
                                                                 GO:0009615 response to virus
                                                                 GO:0009611 response to wounding
                                                                 GO:0006952 defense response
                                                                 GO:0045087 innate immune response
                                                                 GO:0009605 response to external stimulus
                                                                 GO:0042116 macrophage activation
                                                                 GO:0006950 response to stress
                                            Molecular function   GO:0045408 regulation of interleukin-6 biosynthetic process
                                                                 GO:0007249 I-kappaB kinase NF-kappaB cascade
                                                                 GO:0007243 protein kinase cascade
                                                                 GO:0007009 plasma membrane organization and biogenesis
                                                                 GO:0032635 interleukin-6 production
                                                                 GO:0042226 interleukin-6 biosynthetic process
                                                                 GO:0045410 positive regulation of interleukin-6 biosynthetic process
                                                                 GO:0009057 macromolecule catabolic process
                                                                 GO:0009595 detection of biotic stimulus
                                                                 GO:0007250 activation of NF-kappaB-inducing kinase
  Up-Regulated            170               Biological process   None
                                            Molecular function   None
  Down-Regulated          123               Biological process   GO:0006955 immune response
                                                                 GO:0002376 immune system process
                                                                 GO:0051707 response to other organism
                                                                 GO:0009607 response to biotic stimulus
                                                                 GO:0006954 inflammatory response
                                                                 GO:0050896 response to stimulus
                                                                 GO:0009615 response to virus
                                                                 GO:0009611 response to wounding
                                                                 GO:0006952 defense response
                                                                 GO:0045087 innate immune response
                                                                 GO:0009605 response to external stimulus
                                                                 GO:0042116 macrophage activation
                                                                 GO:0006950 response to stress
                                                                 GO:0048518 positive regulation of biological process
                                                                 GO:0002250 adaptive immune response
                                            Molecular function   GO:0045408 regulation of interleukin-6 biosynthetic process
                                                                 GO:0007249 I-kappaB kinase NF-kappaB cascade
                                                                 GO:0007243 protein kinase cascade
                                                                 GO:0007009 plasma membrane organization and biogenesis
                                                                 GO:0032635 interleukin-6 production
                                                                 GO:0042226 interleukin-6 biosynthetic process
                                                                 GO:0045410 positive regulation of interleukin-6 biosynthetic process
                                                                 GO:0009057 macromolecule catabolic process
                                                                 GO:0009595 detection of biotic stimulus
                                                                 GO:0007250 activation of NF-kappaB-inducing kinase
                                                                 GO:0045084 positive regulation of interleukin-12 biosynthetic process

Adv-CAV: advanced cardiac allograft vasculopathy.

###### 

PCR corroboration of differentially expressed genes and Microarray-based FDR.

  Gene      Up/Down   FC    *P*-value (PCR)   FDR (Microarray)
  --------- --------- ----- ----------------- ------------------
  FPRL1     up        2.3   .005              3
  S100A9    up        2.9   .005              3.06
  CXCL10b   up        3.4   .009              1.41
  CXCL10a   up        3.4   .019              1.41
  PRO1073   down      0.5   .045              2.35
  MMP9      up        8.0   .045              3.13
  ENO1      up        1.7   .083              4.60
  FAS       up        1.8   .104              4.17

[^1]: Academic Editor: Kazuhiko Yamada
